Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531518 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL532586 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531329 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531605 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531606 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL13905492 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL17366579 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10086303 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL13905501 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10260659 | 0.91 | CETP (0.43) | CETPNR1I2SCN5ATACR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016067194-A1 | PROCESS FOR THE PREPARATION OF ANACETRAPIB AND AN INTERMEDIATE THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-05-06 | — | — | WO | claimed |
| EP-3402777-B1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3402777-B1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2022075645-A1 | AMINOALCOHOL DERIVATIVE AS PCSK9 INHIBITOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERCHOLESTEREMIA, CONTAINING SAME | 재단법인 대구경북첨단의료산업진흥재단 | 2022-04-14 | — | — | WO | disclosed |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11141410-B2 | Oxazolidinones as taro inhibitors | MERCK SHARP & DOHME CORP (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2007092642-A2 | POLYMER FORMULATIONS OF CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007081571-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007005572-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK & CO., INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005572-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK & CO., INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014357-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | OXA1L, DDO, ALPI | CETP 2701/4885NR1I2 19/4885SCN5A 967/4885 |
| US-11141410-B2 | Oxazolidinones as taro inhibitors | OXA1L, DDO, ALPI | CETP 2701/4885NR1I2 19/4885SCN5A 967/4885 |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | OXA1L, DDO, ALPI | CETP 2701/4885NR1I2 19/4885SCN5A 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.